Geistlich enters into partnership with StimLabs in the USA
Wolhusen/Schlieren/Roswell - Geistlich Pharma has entered into a partnership with StimLabs in the USA. The company from Georgia will exclusively handle national sales of the Derma-Gide wound matrix.
Geistlich Pharma AG, based in Wolhusen in the canton of Lucerne and part of the Geistlich Group from Schlieren in the canton of Zurich, Switzerland, has entered into a distribution partnership with the medtech firm StimLabs from Roswell in the US State of Georgia, further details of which can be found in a press release. From now on, StimLabs is reportedly responsible for handling all commercial activities pertaining to Derma-Gide, the Advanced Wound Matrix developed by Geistlich, in the USA. StimLabs is a pioneer in the development of regenerative medicine with a focus on wound care and surgical applications, as the press release explains further.
Derma-Gide is used to treat wounds that are difficult to heal. The product is approved by the U.S. Food and Drug Administration (FDA) for a variety of indications, including diabetic foot ulcers, venous leg ulcers, surgical wounds and burns. The bi-layered product design mimics the structural organization of human skin, which, according to a product description, facilitates cell ingrowth.
«Geistlich is very pleased to have StimLabs as an exclusive distribution partner of Derma-Gide in the United States to offer our Advanced Wound Matrix to patients suffering from difficult to heal wounds», comments Diego Gabathuler, CEO of Geistlich. StimLabs will leverage its national sales channel to support clinicians in adopting and using this technology, he adds.
Geistlich is a global leader in the field of regenerative technologies, as StimLabs CEO John Daniel explains. He expressed his satisfaction at adding a «high quality, clinically proven xenograft option to our portfolio».
